key: cord-0763419-xdk07uc5 authors: Sinclair, J. E.; Zhu, Y.; Xu, G.; Ma, W.; Shi, H.; Ma, K.-L.; Cao, C.-F.; Kong, L.-X.; Wan, K.-Q.; Liao, J.; Wang, H.-Q.; Arentz, M.; Redd, M.; Gallo, L. A.; Short, K. R. title: The role of pre-existing chronic disease in cardiac complications from SARS-CoV-2 infection: A systematic review and meta-analysis date: 2020-06-23 journal: nan DOI: 10.1101/2020.06.21.20136622 sha: cf7e36cd1ade2c3acec8eece439cf5b29bb77cca doc_id: 763419 cord_uid: xdk07uc5 ABSTRACT Importance: SARS-CoV-2 is associated with multiple direct and indirect effects to the heart. It is not yet well defined whether patient groups at increased risk of severe respiratory disease due to SARS-CoV-2 infection also experience a heightened incidence of cardiac complications. Objective: We sought to analyse the role of pre-existing chronic disease (chronic respiratory illness, cardiovascular disease (CVD), hypertension and diabetes mellitus) in the development of cardiac complications from SARS-CoV-2. Data Sources: We retrospectively investigated published (including pre-prints), publicly released, de-identified, data made available between Dec 1, 2019, and May 11, 2020. Information was accessed from PubMed, Embase, medRxiv and SSRN. Study Selection: 379 full-text articles were reviewed and 321 excluded for lack of original research, irrelevance to outcome, inappropriate cohort, or small patient numbers (case reports of <10 patients). Data were extracted from two studies and the remaining 56 contacted to request appropriate data, to which three responded with data contributions. A final of five studies were included. Data Extraction and Synthesis: This systematic review was conducted based on PRISMA and MOOSE statements. Included studies were critically appraised using Newcastle Ottawa Quality Assessment Scale (NOS). Data were extracted independently by multiple observers. A fixed-effects model was selected for the meta-analysis based on relatively low heterogeneity between the studies (I2<50%). Main Outcome and Measures: Cardiac complications were determined via blood levels of cardiac biomarkers above the 99th percentile of the upper reference limit, abnormalities in electrocardiography, and/or abnormalities in echocardiography. Results: SARS-CoV-2-infected patients who developed cardiac complications were, on average, 10 years older than those that did not. Pooled analyses showed the development of cardiac complications from SARS-CoV-2 was significantly increased in patients with underlying chronic respiratory illness (OR 2.88[1.45,5.71]), CVD (OR 5.12[3.09,8.48]), hypertension (OR 4.37[2.99,6.39]) and diabetes mellitus (OR 2.61[1.67,4.09]). Conclusions and Relevance: Older age and pre-existing chronic respiratory illness, CVD, hypertension, and diabetes mellitus may represent prognostic factors for the development of additional cardiac complications in COVID-19, highlighting the need for a multidisciplinary approach to chronic disease patient management and providing justification for a larger scale observational study. Cardiac complications were determined via blood levels of cardiac biomarkers above the 99 th percentile of the upper reference limit, abnormalities in electrocardiography, and/or abnormalities in echocardiography. Results: SARS-CoV-2-infected patients who developed cardiac complications were, on average, 10 years older than those that did not. Pooled analyses showed the development of cardiac complications from SARS-CoV-2 was significantly increased in patients with underlying chronic respiratory illness ( Older age and pre-existing chronic respiratory illness, CVD, hypertension, and diabetes mellitus may represent prognostic factors for the development of additional cardiac complications in COVID-19, highlighting the need for a multidisciplinary approach to chronic disease patient management and providing justification for a larger scale observational study. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. . https://doi.org/10.1101/2020.06.21.20136622 doi: medRxiv preprint INTRODUCTION SARS-CoV-2 causes a broad range of respiratory symptoms, ranging from subclinical disease to viral pneumonia. 1 However, it is increasingly apparent that SARS-CoV-2 also causes a variety of extra-respiratory complications. 1 Specifically, SARS-CoV-2 infection has been associated with acute myocardial injury, myocarditis, arrhythmias, venous thromboembolism and other de novo cardiac complications. [2] [3] [4] [5] [6] The development of these complications is likely enhanced by experimental testing of antimalarial and antiviral drugs, which have known cardiovascular side effects. [4] [5] [6] [7] [8] [9] [10] [11] [12] Although prevalence estimates vary, data from China suggests that approximately 7% of patients infected with SARS-CoV-2 develop cardiac injury (defined as elevated high-sensitivity cardiac troponin I or new echocardiographic; ECG abnormalities). 13 This prevalence increases to 22% in patients who required ICU care. 13 However, at present, the role of pre-existing chronic disease in the cardiac complications of COVID-19 remains to be elucidated. Pre-existing chronic respiratory disease, CVD, hypertension and diabetes mellitus have each been associated with increased rates of hospitalization, ICU admission, and death from the respiratory complications of SARS-CoV-2. 13-26 It is not yet well defined whether these patient groups are also at an increased risk of SARS-CoV-2 associated cardiac injury. Some small studies have shown that patients with pre-existing CVD are at a higher risk of myocarditis and/or myocardial infarction from SARS-CoV-2. 3,27,28 A retrospective, single-centre case series of 187 patients with COVID-19 also found that pre-existing CVD increased the risk of cardiac injury (as defined by troponin elevation) (54.5% vs 13.2%) and mortality compared with patients without CVD. 3 Similarly, a meta-analysis of 28 observational studies found SARS-CoV-2 associated cardiac injury biomarkers to be related to a history of hypertension but not diabetes mellitus. 29 In contrast, Zhu and colleagues found that individuals with type 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 23, 2020. . https://doi.org/10.1101/2020.06.21.20136622 doi: medRxiv preprint diabetes mellitus had a greater occurrence of acute heart injury (7.3% versus 3.0%) than individuals without diabetes. 30 There is a clear need to better understand the role of patient host factors in the extra-respiratory complications of SARS-CoV-2 infection. Here, we analysed the currently available literature on the role of pre-existing chronic respiratory illnesses, CVD, hypertension and diabetes mellitus in the prevalence of SARS-CoV-2 associated cardiac injury. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 23, 2020. . https://doi.org/10.1101/2020.06.21.20136622 doi: medRxiv preprint We retrospectively investigated published and pre-printed, publicly released and de-identified data made available between Dec 1, 2019, and May 11, 2020. Information was accessed from four databases (PubMed, Embase, medRxiv and SSRN) using the following search terms: ("covid-19"[All Fields]) OR ("SARS-CoV-2"[All Fields]) OR ("novel coronavirus" [All Fields]) AND ("cardi*"[All Fields] OR "diabetes"[All Fields]). A total of 1124 articles were retrieved after duplicates were removed (available in either English or Chinese), following which 745 records were removed after screening by title and abstract. 379 full-text articles were reviewed. Of these, 321 articles were excluded because i) they did not include original research, ii) they were not relevant to the outcome, iii) they described an inappropriate patient population and/or iv) they described case reports of <10 patients. Of the remaining 58 studies that were deemed eligible, due to their containing data on patient pre-existing disease and cardiac complications as an outcome, two contained the required data format and these were extracted. The authors of the remaining 56 studies were contacted to request appropriate data (as they presented only aggregate data that did not specify the cross-over between preexisting chronic disease and outcome), to which three groups responded with data contributions. Thus, a final of five studies were included in the meta-analysis (31-35). The selection process is shown in Figure 1 . Extracted variables were aggregate data of median age, sex, underlying chronic disease (chronic respiratory illness, CVD, hypertension and diabetes mellitus) and the occurrence of cardiac complications as an outcome. Patients with co-morbidities were included in all . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 23, 2020. . https://doi.org/10.1101/2020.06.21.20136622 doi: medRxiv preprint applicable categories. For cases in which the data source reported more than one type of comorbid CVD separately (such as prevalence of both chronic heart failure and coronary heart disease within their cohort), only the group with the most cases was included to avoid patient double up and overrepresentation of co-morbid CVD. Median data for age were analysed individually using a Mann-Whitney U test. R version 4·0·0 software was used to analyse sex distribution as well as pre-existing chronic disease and cardiac outcomes through meta analysis. Heterogeneity among studies was assessed by using the Q statistic with a P value <.05, indicating the presence of significant heterogeneity, and quantified by using the I 2 statistic. A fixed-effects model was used as for all parameters I 2 < 50%. Cardiac complications were defined as one or more of the following: blood levels of cardiac biomarkers (TNI or CK-MB) above the 99 th percentile upper reference limit, 36-38 and/or abnormalities observed in clinical assessments of the patients' heart function, including electrocardiography (ECG) 39-43 or echocardiography. 40-44 The included studies were critically appraised using Newcastle Ottawa Quality Assessment Scale (NOS). 45 High-quality studies were defined as studies fulfilling NOS score of minimum . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. . https://doi.org/10.1101/2020.06.21.20136622 doi: medRxiv preprint We identified 1124 articles that described pre-existing chronic disease and cardiac complications of SARS-CoV-2, rejected 1066 articles due to a lack of sufficient and/or appropriate data and derived a total of 58 articles. Five of these studies were subsequently used in a meta-analysis ( Fig. 1) , all of which were high quality (Table 1) . Baseline characteristics of the patient populations as well as other relevant data are listed in Table 2 . with SARS-CoV-2 associated cardiac complications were, on average, 10 years older than in those who did not ( Table 2) . Males were equally represented amongst patients with and without SARS-CoV-2 cardiac complications, both in an individual analysis of the five studies (Table 2 ) and in a metaanalysis of the pooled data ( Fig. 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. This meta-analysis shows that older age, and pre-existing chronic respiratory disease, CVD, hypertension and diabetes mellitus are all risk factors for the development of cardiac complications associated with SARS-CoV-2 infection. A pooled analysis of five studies identified a significant association between pre-existing CVD and the risk of SARS-CoV-2 cardiac complications. This is consistent with previous observations that 30% of patients with SARS-CoV-2 cardiac injury had a history of coronary heart disease. 3, 28 The reason for this association remains unclear. These data may be the result of pre-existing CVD leading to a functionally impaired immune system, excessive cytokine release, 5 endothelial dysfunction, increased procoagulant blood activity, rupturing of coronary atherosclerotic plaques, 48 and the formation of an occlusive thrombi. 49 Furthermore, an acute inflammatory response to SARS-CoV-2 can lead to ischemia in the presence of preexisting CVD. 5 Thus, SARS-CoV-2 infection may either precipitate a type 1 myocardial infarction, increase myocardial demand leading to worsening ischemia and necrosis (type 2 myocardial infarction), or increase metabolic demand that leads to heart failure and death. 5 An alternative explanation is the elevated levels of myocardial angiotensin-converting enzyme (ACE)-2 in these patients, both as a result of heart failure, 1,50 post-myocardial infarction, 51 and/or as a consequence of long-term treatment with ACE inhibitors/angiotensin II receptor blockers (ARBs), 52, 53 permitting increased viral entry directly to cardiomyocytes and perivascular pericytes. 9,54 However, the role of ACE2 in this process remains controversial and requires experimental validation. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. . https://doi.org/10.1101/2020.06.21.20136622 doi: medRxiv preprint 1 0 The meta-analysis performed herein also found that chronic respiratory illness significantly increased the incidence of SARS-CoV-2 cardiac complications. It is possible that these data reflect the established indirect association between severe respiratory disease and both subsequent acute cardiovascular event and longer-term cardiovascular disease. [55] [56] [57] [58] [59] Specifically, pulmonary damage in individuals with chronic respiratory disease may predispose them to increased hypoxemia upon acute infection, which can then manifest into ischemic heart damage, 55,58 alteration of right ventricle structure and function, 58 heart failure, 56,59 atrial fibrillation, 59 peripheral vascular disease, 59 and coronary heart disease. 56 However, chronic lung disease has not been consistently associated with SARS-CoV-2 acute respiratory distress syndrome (ARDS) and hypoxemia, 60 The association between underlying diabetes mellitus and cardiac complications from SARS-CoV-2 may be attributable to a multitude of other effects induced by abnormal circulating substrates, including hyperglycaemia, and/or the co-existence and complex interactions with . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. . https://doi.org/10.1101/2020.06.21.20136622 doi: medRxiv preprint other, even subclinical, conditions in this patient group. 63 In response to changes in substrate availability, for example, the diabetic heart becomes increasingly dependent on fatty acids as a fuel source, which decreases work efficiency, and dysregulates responses to hypoxia. 64 These metabolic changes may predispose individuals with diabetes to an increased risk of ischemic cardiac injury upon SARS-CoV-2 infection. The contribution of underlying diabetes mellitus to the risk of SARS-CoV-2 cardiac complications, however, depends largely on the duration of pre-existing disease. 65 There are several limitations in our study. Firstly, the limited number of studies that met the selection criteria meant that it was not possible to correct for other variables that may confound these results. For example, it is possible that our observations were confounded by the strong effect that age has on cardiovascular health. Similarly, we cannot exclude the possibility that the associations observed herein are due, at least in part, to treatments for severe COVID-19 that may damage the heart. Indeed, the experimental therapeutic hydroxychloroquine has been associated with QT interval prolongation, cardiomyopathy and heart failure. 8-10 This is likewise the case for treatments for underlying conditions, such as ACE inhibitors and ARBs which, while not known to damage the heart, may interfere with how the immune system targets the virus. 52 Information regarding which, if any, therapeutics used in these cohorts of patients was not consistently available. We anticipate that as more data on the cardiac complications become available it will be possible for future analyses to correct for these and other confounders. A second important limitation of the present analysis is the limited geographical range of the included studies. To encompass important regional and national variations in patient . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. . https://doi.org/10.1101/2020.06.21.20136622 doi: medRxiv preprint populations and disease severity it will be necessary to validate these data in other locations as the data becomes available. Despite the above limitations, these data have important implications for patient care. Patients with one or more underlying medical conditions should be closely monitored for both severe respiratory and extra-respiratory COVID-19 complications. Furthermore, the exploratory use of medications that are independently associated with cardiac complications should be considered with caution in these patient groups and perhaps bypassed in favour of lower-risk treatment options. There is thus a clear need for a multidisciplinary, collaborative team to manage the complexity of COVID-19 illness observed in patients with one or more underlying chronic disease. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. in the study design, collection, analysis, and interpretation of data, report writing, or the decision to submit for publication. The authors declare no conflict of interest. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. . https://doi.org/10.1101/2020.06.21.20136622 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. . https://doi.org/10.1101/2020.06.21.20136622 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 23, 2020. . https://doi.org/10.1101/2020.06.21.20136622 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 23, 2020. . https://doi.org/10.1101/2020.06.21.20136622 doi: medRxiv preprint COVID-19 and cardiovascular disease Clinical features of patients infected with 2019 novel coronavirus in Wuhan Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection COVID-19 and the cardiovascular system Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19) Interim guidance for basic and advanced life support in adults, children, and neonates with suspected or confirmed COVID-19: from the Emergency Cardiovascular Care Committee and Get With the Guidelines® -1 Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centred, retrospective, observational study Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention Patients with diabetes are at higher risk for severe illness from COVID-19 Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan Angiotensin converting enzyme 2: SARSCoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2 Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure Pulmonary diseases and the heart. Circulation Coronary heart disease and heart failure in asthma, COPD and asthma-COPD overlap Acute myocardial infarction and influenza: a meta-analysis of case-control studies Pulmonary heart disease: the heart-lung interaction and its impact on patient phenotypes Association of cardiovascular disease with respiratory disease Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?